Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

Sponsored by Bristol Myers Squibb

Aug 21, 2023 5:05 am

Author(s):

Cristina Arriens, Anca Askanase, Richard Furie, Eric Morand, Ronald van Vollenhoven, Kevin Connors, Monica Davey, Nikolay Delev, Vaishali Shah, Anna Stevens, Thomas Wegman, Coburn Hobar

Abstract or description:

Dr. Cristina Arriens discusses the study design and recruitment methodology for the phase 3 POETYK SLE-1 (NCT05617677) and POETYK SLE-2 (NCT05620407) studies to assess the safety, efficacy, and
tolerability of deucravacitinib in active SLE. This poster presentation provides information regarding the enrollment process of additional study sites for both trials.

For more information, please visit the following links:

https://clinicaltrials.gov/ct2/show/NCT05617677

https://clinicaltrials.gov/ct2/show/NCT05620407

https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT05620407.html#trialSites

https://www.bmsstudyconnect.com/content/studyconnect/us/en/clinical-trials/NCT05617677.html#trialSites

Video Transcript

Safety and Efficacy of a JAKi in Patients With Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 From the SELECT-CHOICE Study

Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension

Non-Pharmacologic Interventions for Rheumatoid Arthritis

Sustained Remission From Weeks 16 to 52 and Weeks 24 to 52 in Patients Treated With Sarilumab: Post-hoc Analysis of SAPHYR Trial in Patients With Polymyalgia Rheumatica